3,296 Shares in Verona Pharma PLC American Depositary Share $VRNA Purchased by Invesco Ltd.

Invesco Ltd. purchased a new stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 3,296 shares of the company's stock, valued at approximately $209,000.

Several other institutional investors have also recently bought and sold shares of the business. NBC Securities Inc. bought a new stake in shares of Verona Pharma PLC American Depositary Share during the first quarter worth $34,000. Vermillion Wealth Management Inc. bought a new stake in shares of Verona Pharma PLC American Depositary Share during the fourth quarter worth $46,000. GF Fund Management CO. LTD. bought a new stake in shares of Verona Pharma PLC American Depositary Share during the fourth quarter worth $72,000. Advisors Preferred LLC raised its position in shares of Verona Pharma PLC American Depositary Share by 65.4% during the first quarter. Advisors Preferred LLC now owns 1,599 shares of the company's stock worth $94,000 after acquiring an additional 632 shares during the last quarter. Finally, Avanza Fonder AB bought a new stake in shares of Verona Pharma PLC American Depositary Share during the first quarter worth $100,000. Institutional investors own 85.88% of the company's stock.

Analyst Upgrades and Downgrades

VRNA has been the subject of a number of recent analyst reports. Cantor Fitzgerald upped their price objective on Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the company an "overweight" rating in a report on Wednesday, June 11th. Piper Sandler cut Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 10th. Cowen cut Verona Pharma PLC American Depositary Share from a "buy" rating to a "hold" rating in a research note on Wednesday, July 9th. TD Cowen cut Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, July 9th. Finally, Canaccord Genuity Group cut Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and set a $107.00 target price for the company. in a research note on Wednesday, July 9th. Two analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $109.00.

Insider Buying and Selling at Verona Pharma PLC American Depositary Share

In related news, CFO Mark W. Hahn sold 208,912 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $13.14, for a total transaction of $2,745,103.68. Following the completion of the transaction, the chief financial officer directly owned 12,464,968 shares of the company's stock, valued at $163,789,679.52. This trade represents a 1.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO David Zaccardelli sold 208,912 shares of the business's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $13.14, for a total value of $2,745,103.68. Following the completion of the transaction, the chief executive officer directly owned 13,376,144 shares in the company, valued at $175,762,532.16. This represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 620,584 shares of company stock worth $8,025,674 over the last 90 days. Company insiders own 4.80% of the company's stock.

Verona Pharma PLC American Depositary Share Stock Up 0.0%

Shares of VRNA stock traded up $0.03 on Friday, hitting $106.43. 918,692 shares of the stock were exchanged, compared to its average volume of 1,254,697. The business has a 50-day moving average of $104.80 and a 200 day moving average of $83.57. Verona Pharma PLC American Depositary Share has a fifty-two week low of $27.54 and a fifty-two week high of $106.45. The company has a current ratio of 10.71, a quick ratio of 10.54 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $8.71 billion, a P/E ratio of -107.50 and a beta of 0.14.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.14. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%.The firm had revenue of $103.14 million for the quarter, compared to analyst estimates of $90.41 million. Equities analysts anticipate that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current year.

Verona Pharma PLC American Depositary Share Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.